审查当前和即将到来的二线治疗初级胆汁胆道炎的治疗方法
Nicholas A Cumpian1, Gina Choi2, Sammy Saab3,4
1Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.
Digestive diseases and sciences
|December 2, 2024
概括
新的疗法为初级胆管胆炎 (PBC) 患者提供了有效的选择,这些患者对乌尔索西胆酸 (UDCA) 反应不佳. 第三阶段试验显示,这些二线治疗显著改善肝酶并满足关键终点.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 原发性胆道胆炎 (PBC) 治疗历史上依赖于乌尔索氧胆酸 (UDCA).
- 很大一部分患者 (近40%) 对UDCA.表现出不充分的反应.
- 这就需要探索和评估替代的二线疗法.
研究的目的:
- 系统地审查和评估二线治疗PBC的有效性和安全性.
- 专注于来自第三阶段临床试验的数据.
主要方法:
- 对主要数据库 (PubMed,Medline,ClinicalTrials.gov) 的系统审查.
- 包括第二线PBC治疗的已公布的第三期试验数据.
- 对有效性终点的分析,包括性酸酶 (ALP) 水平和总 bilirubin (TB).
主要成果:
- 四个第三阶段的试验评估了obeticholic 酸,贝扎菲布拉特,seladelpar 和elafibranor.
- 与安慰剂相比,所有疗法都在初级终点上显示了统计学上显著的改善.
- 从基线来看,在所有试验中都观察到ALP的显著降低,正常化率因治疗而异.
- 伊拉非布拉诺和塞拉德帕也显著改善了 ().
- 由于不良事件导致的停药率在1%至14%之间.
结论:
- 所有评估的二线疗法都达到研究终点.
- 有效的二线治疗选择可用于患有PBC的患者.
- 目前正在对这些疗法进行持续的长期评估.
关键词:
在阿尔卑斯山,阿尔卑斯山.贝扎纤维化 贝扎纤维化这是Elafibranor.在OCA中,OCA是OCA.在PBC中,PBC是PBC.第二线的第二线.塞拉德尔帕尔 (Seladelpar) 是一个UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA UDCA更多相关视频
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
77
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
77
01:30Acute Pancreatitis II: Clinical Manifestations and Management
111
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
111
01:29Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
01:17Chronic Bowel Disorders: Introduction
414
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
414
01:26Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98